Medicare AdvantageCoverageMedium impact
MA08.011i, Erythropoiesis Stimulating Agents (ESAs)
Independence Blue Cross·Nephrology, Oncology, Hematology +1 more·Medical Policy
Effective date
Jun 15, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.011i for Erythropoiesis Stimulating Agents (ESAs) has been updated with changes to medical necessity criteria and medical coding requirements. This affects billing and coverage determination for ESA medications used to treat anemia, particularly in chronic kidney disease and cancer patients.
Action Required
Before June 15, 2026: Billing team must review updated medical necessity criteria for ESA medications and update documentation requirements in billing system. Providers should ensure proper documentation of medical necessity before prescribing ESAs for Medicare Advantage patients. Verify any coding changes are implemented in billing software to prevent claim denials.